| Name | Title | Contact Details |
|---|
Modern Meadow was founded on the belief that customers should not have to choose between performance and sustainability. Additionally, we believe that people should not have to choose between a career that helps them achieve their personal goals and a career with purpose. Achieving both personal and professional goals with purpose is possible at Modern Meadow, and we invite qualified professionals to apply for positions of interest. At the intersection of biotechnology and material science, Modern Meadow designs materials solutions for the way we want the world to perform. We are pioneers of biofabrication, building with biology. This enbables us to harness unique properties of proteins to move the world away from petrochemical and animal-derived inputs, leading a shift to the bioeconomy. Modern Meadow Biofabricated Materials offer the world a new way forward. By introducing a more effective, more responsible, and readily available supply, we are shifting demand away from extractive practices and toward a sustainable bioeconomy. Our team is engaged in exciting work to enable us all to move beyond sustainability to real world impact. Our philosophy and sustainability principles help us stay focused on the most critical environmental issues and challenge us to design our products and systems in the most sustainable manner. But we cannot build a bioeconomy alone. We are partnering with companies, developing bio-based supply chains, and speaking with businesses looking to design for sustainability from the start. Together we can create new coalitions to build out the environmentally conscious alternatives our planet desperately needs.
Bedrocan is an experienced producer of pharmaceutical-grade medicinal cannabis with over 13 years growing expertise in global markets. We provide patients and healthcare professionals with safe, effective and consistent medicine for the appropriate management of diagnosed health conditions. Our strains of pharmaceutical-grade cannabis are used by thousands of patients in seven countries, including Canada. We provide three fully standardized products, and as a result, our standardized strains are the choice for researchers and academics who study the medical effects of cannabis.
Kudo Biotechnology is a global CDMO, providing world-class, end-to-end mRNA manufacturing solutions, all under one roof. Kudo has state-of the-art clinical GMP manufacturing facilities and labs in Boston, China & Singapore, making pDNA, mRNA and LNP. Kudo Bio differentiates by being a one-stop stop for all your mRNA manufacturing needs, by streamlining the process, removing bottlenecks and ensuring ease in your CMC. Our performance matches and surpasses industry-leading yields & efficiencies across all stages of the process. Our speed of 6.5 months from sequence to GMP mRNA-LNP exceeds industry platinum standards, and our quality is superior to competitors while maintaining full compliance with global regulatory requirements. Kudo Bio has a track record of accomplishing end-to-end GMP manufacturing with products entering the clinic, and successfully completing multiple batches of process validation after international technology transfer. We have an industry-leading manufacturing cGMP facility with capacity to make up to 50 GMP batches annually, with deep technology partnerships enabling access to scale-up expertise & production know-how. Finally a comprehensive quality management system with QA/QC capabilities which meet major regulatory agencies compliance requirements is paramount to delivering products to customers around the world.
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum`s proprietary product engine, FulcrumSeekâ„¢, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.
Immport Therapeutic Inc is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.